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disease management program, signiﬁcantly lower costs were
noted during Year 1 which continued and expanded through
Year 2 relative to matched comparators. Beyond claims analyses,
however, incremental cost-effectiveness of disease management
programs must also consider program-speciﬁc expenditures and
clinical outcome measures.
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OBJECTIVE: To examine whether physicians’ practice specialties
are associated with the types of anti-diabetic treatments for
patients with type 2 diabetes (T2D). METHODS: A retrospective
study design was used based. All T2D patients’ (N = 1,819,323)
medication histories in a 12 month period were examined and
classiﬁed into 9 treatment types (no anti-diabetic medication, oral
anti-diabetic medication (OAD), basal insulin only, prandial
insulin only, basal insulin with OAD, prandial insulin with OAD,
basal/prandial insulin, basal/prandial insulin(including premixed
insulins) with OAD, other insulin regimens). Physicians practice
specialties were classiﬁed into ﬁve categories (family medicine,
internal medicine, other primary care specialists, endocrino-
logists, other specialties). A two-way contingency table was
created with Chi-square test and Fisher’s exact test to examine the
possible association between physicians’ practice specialty and the
types of anti-diabetic treatments they prescribed.RESULTS: Both
the Chi-square test and the Fisher’s exact test had p < 0.0001,
indicating that physicians’ practice specialty and their patients’
anti-diabetic treatment choices were statistically signiﬁcantly
associated. The contingency table suggests that the percent of
patients receiving no anti-diabetic medications varied across spe-
cialties from 36.0% in patients who visited an endocrinologist to
49% and 52% in patients who visited a family medicine physician
or internist, respectively. The percent of patients receiving OAD
only varied across specialties from 33.1% in patients who visited
an endocrinologist to 46.8% in patients who saw a family medi-
cine physician, and 43.6% in patients under the care of an
internist. And the percent of patients receiving insulin as part of
their regimen varied across specialties from4.12% in patientswho
visited a family medicine physician to 12.3% in patients who
visited an endocrinologist. CONCLUSION: Physicians’ practice
specialty is strongly associated with anti-diabetic medications
prescribed for patients with T2D. Further research to examine
outcomes differences across physician specialties is needed.
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OBJECTIVE: In the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial (a 10-year, 70 site study of diabetes
treatments), four health state preference measures (HSPMs),
which vary in theoretical constructs, are being collected. Our
objectives were to compare baseline values of the feeling
thermometer (FT), the Health Utilities Index, Mark 2 and Mark
3 (HUI-2 and HUI-3), and the SF-6D, derived from the Short
Form 36 and to explore associations between each HSPM
and 29 baseline clinical and demographic characteristics.
METHODS: Participants (n = 2053) were randomly selected for
the cost effectiveness sub-study of ACCORD. To compare the
HSPMs, we determined correlations between the measures, by
overall score and within each quartile range. We used multivari-
ate regression models to identify relationships between clinical
and demographic characteristics for each HSPM. RESULTS:
The mean  standard deviation HSPMs were: FT = 0.756 
0.167, HUI-2 = 0.823  0.146, HUI-3 = 0.712  0.260, and
SF-6D = 0.684  0.085. Although all 4 measures were signiﬁ-
cantly correlated with each other (Spearman r = 0.29–0.84
(p < 0.0001); relationships were weaker between the FT and the
other measures (0.29–0.38) and strongest between the two HUI
measures (0.84). By quartiles of HSPM, signiﬁcant correlations
were more common at the lowest quartile. In multivariate
regression analyses, we identiﬁed signiﬁcant associations
(p < 0.01) between HSPM values and age (positive), gender
(lower for females), years of education (positive), and race
(lower for non-white). Clinical characteristics inversely associ-
ated with HSPMs were duration of diabetes, current smoking,
secondary cardiovascular disease, total cholesterol, waist cir-
cumference, and body mass index. Number of medications
(blood pressure, glycemic, or lipid) were not signiﬁcantly
associated with HSPMs. Glycosylated hemoglobin values were
inversely related to FT only. CONCLUSION: Our results
suggest that the four instruments,result in different HSPM
values. Relationships with clinical and demographic variables
vary by HSPM. Therefore, results of cost-effectiveness results
may be impacted by the speciﬁc HSPM applied.
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OBJECTIVE: The aim of this study was to collect comparable
and reliable data about consumption of drugs for treatment of
diabetes mellitus in Slovakia during the period 1996–2006.
METHODS: Data of wholesalers (following ATC/DDD), who
are legally obliged provide this information to the Slovak Insti-
tute for Drug Control, was used for the analysis. The results
were expressed in the numbers of the packages, ﬁnance units (€)
and deﬁned daily doses per 1000 inhabitants per day (DID).
RESULTS: The collected data shows a moderate increases in the
antidiabetic’s consumption from 1996 to 2006 in term of DID (in
1996 (27.03), in 2001 (32.62) and in 2006 (37.90). A slight
increase in A10AB group (Insulins and analogues, fast-acting) in
1996 (1.88), in 2001 (2.79) and in 2006 (4.64), a slight decrease
in A10AC group (Insulins and analogues, intermediate-acting) in
1996 (4.25), in 2001 (3.74) and in 2006 (3.35), a moderate
increase in A10AD (Insulins and analogues, intermediate-acting
combin.) in 1996 (0.51), in 2001 (2.36) and in 2006 (3.25), a
steady increase in A10AE (Insulins and analogues, long-acting) in
2001 (0.03) and in 2006 (0.89), a dramatic increase in A10BA
(Biguanides) in 1996 (4.45), in 2001 (5.75) and in 2006 (9.46),
relatively stable consumption in A10BB (Sulfonamides, urea
derivatives) in 1996 (15.33), in 2001 (17.19) and in 2006 (14.76)
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and a moderate increase in A10BD (Biguanides and sulfonamides
in combination) in 2001 (0.07) and in 2006 (1.41) in term of
DID can be seen from this analysis. Financial expenditures for
antidiabetics were (in 1996 (€9,772,000), in 2001 (€18,169,000)
and in 2006 (€26,541,000). CONCLUSION: Inseparable com-
ponents of the Slovak drug policy must be viewed realistically
with regard to the antidiabetics’ consumption. Adherence to
principles of diabetes mellitus treatment’s guidelines lead to fun-
damental short and long term ﬁnancial savings within health care
systems.
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OBJECTIVE: In the treatment of type 2 diabetes (T2D), achiev-
ing glucose control often requires multiple therapies. The class of
antidiabetic agents called incretin mimetics offers an alternative
mechanism to diabetes management. This work describes the
baseline demographic and clinical characteristics of a T2D popu-
lation in a primary care setting before they initiated treatment
with the incretin mimetic, exenatide. METHODS: Patients were
extracted from the General Electric (GE) electronic medical
record (EMR) database from January 1, 2000 through June 30,
2007. Patients with T2D (diagnosis, oral antidiabetic drug pre-
scription, two consecutive fasting blood glucose levels 126 mg/
dL, or A1C 7.0%) were identiﬁed, as were those with at least
one prescription for exenatide. Using these data, descriptive sta-
tistics were calculated for these populations. RESULTS: Of the
11,601 patients with a prescription for exenatide, nearly all had
T2D (96%). A total of 7425 of the patients with a prescription of
exenatide were 18 years of age and had at least 395 days of
records prior to the index date. Compared to the 510,623 T2D
patients on other treatments with these same age and records
restrictions in the GE EMR, those patients on exenatide were
signiﬁcantly heavier (204.2 lbs. vs. 244.2 lbs. (p < 0.001)) with
higher BMI (32.9 kg/m2 vs. 38.7 kg/m2 (p < 0.001)). A larger
percentage of the exenatide population was obese or extremely
obese than the population on other treatments (89% vs. 61%
(p < 0.001)). The portion of the exenatide population with base-
line A1C 9.0 was higher than that of the population on other
treatments (56% vs. 12% (p < 0.001)) and, compared to the
total, exenatide patients had signiﬁcantly higher mean A1Cs
(7.2% vs. 8.1% (p < 0.001)). CONCLUSION: These results
suggest that exenatide is being added to T2D treatment regimens
in obese patients with relatively high A1C levels to achieve better
diabetes control.
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OBJECTIVE: To assess the extent of, exposure to, and medica-
tion expenditure trends associated with insulin-treated patients
reaching the Medicare Part D standard beneﬁciary prescription
coverage gap (i.e., ‘doughnut hole’) and catastrophic coverage.
METHODS: Patients receiving various insulin formulations and
mixtures throughout 2006 were investigated via a prescription
transaction-level retrospective database that captured 50% of all
retail dispensing activity within the U.S. Analyses focused upon
the coverage gap and catastrophic coverage within standard ben-
eﬁciaries regarding: 1) the number of patients entering; 2) the
month of entry; and 3) medication expenditures. RESULTS:
Overall, 324,430 Medicare beneﬁciaries received an insulin
regimen in 2006, consisting of 41% dual-eligibles (n = 131,611),
32% low-income subsidiaries (n = 105,151), and 27% standard
beneﬁciaries (n = 87,668). Across all coverage groups, oral
antidiabetic agents and insulin comprised 66–72% of monthly
drug expenditures. Of those potentially being exposed to a cov-
erage gap, 46% reached the ‘doughnut hole’ (12% of all Part D
beneﬁciaries) and 12% entered catastrophic coverage (3% of all
Part D beneﬁciaries). Among the near 55,300 standard beneﬁ-
ciaries (63% of 87,668) enrolling in Part D by March 2006,
prescription expenditures peaked in the month prior to entering
the coverage gap, followed by an immediate 20–25% drop in the
month thereafter. Decreased expenditures broadly corresponded
to a decrease in the number of diabetes agents dispensed. CON-
CLUSION: This analysis found that 46% of all insulin-treated
patients covered by the Medicare Part D standard beneﬁt (12%
of all Part D beneﬁciaries) were exposed to the coverage gap in
2006, characterized by a shifting of full ﬁnancial responsibility to
beneﬁciaries for outpatient medications. Entry was followed by a
20–25% decrease in expenditures and, more generally, in the
number of diabetes agents received. These ﬁndings warrant
continued evaluation of coverage policies and any subsequent
cost-shifting or deferrals in care that may occur, particularly for
chronic diseases.
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OBJECTIVE: Use of adjunctive insulin therapy with oral anti-
hyperglycemic agents in patients with type 2 diabetes (T2D) has
been growing in the US following demonstration in the U.K.
Prospective Diabetes Study that intensive therapy regimens
increased glycemic control and reduced microvascular complica-
tions. The primary objective in this study was to compare the
effect of analog insulin with human insulin usage on all-cause
and diabetes-attributable direct health care costs and utilization
in patients with type 2 diabetes. METHODS: Using the
MarketScan Research Database, commercially insured patients
were selected who initiated insulin therapy with analog or human
insulins during 2001–2005, had no insulin claims 12 months
prior to starting therapy, and a type 2 diabetes diagnosis during
the study period. Patients were followed 12-months from insulin
therapy initiation, and were stratiﬁed according to their therapy
as receiving analog insulin only (n = 18,205), human insulin only
(n = 7035), or both analog and human insulins (n = 5040).
Health care utilization and expenditures were compared between
treatment groups and between pre-index and post-index periods.
Generalized multi-valued propensity score weighting was used to
control for observable differences in distributions of pretreat-
ment variables among treatment groups. RESULTS: Although
mean costs for insulin and other prescriptions were lowest for
patients receiving only human insulin, mean post-index total
all-cause health care costs for analog insulin patients ($17,059)
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